(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 September 2004 (23.09.2004)

PCT

(10) International Publication Number
WO 2004/081007 A1

(51) International Patent Classification[7]: C07D 471/04, A61K 31/495

(21) International Application Number: PCT/IB2004/000499

(22) International Filing Date: 23 February 2004 (23.02.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/453,925 12 March 2003 (12.03.2003) US

(71) Applicant *(for all designated States except US)*: **PFIZER PRODUCTS INC.** [US/US]; Eastern Point Road, Groton, CT 06340 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **BRIGHT, Gene, Michael** [US/US]; 329 Tyler Avenue, Groton, CT 06340 (US). **BRODNEY, Michael, Aaron** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US). **WLODECKI, Bishop** [US/US]; Pfizer Global Research and Development, Eastern Point Road, Groton, CT 06340 (US).


(74) Agents: **LUMB, J., Trevor** et al.; Pfizer Inc., 201 Tabor Road, Morris Plains, NJ 07950 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,

[Continued on next page]

(54) Title: PYRIDYLOXYMETHYL AND BENZISOXAZOLE AZABICYCLIC DERIVATIVES



(I)



(II)

(57) Abstract: An aminomethylpyridyloxymethyl/benzisoxazole substituted azabicyclic compound according to formula (I) a pharmaceutical composition comprising same, and a method of treating one or more CNS or other disorders, including concurrent treatment of disorders such as chizophrenia and depression. Or the (R) or (S) enantiomer thereof, or the *cis* or *trans* isomer thereof, or a pharmaceutically acceptable salt, solvate or prodrug thereof, or of any of the foregoing, wherein m is 0 or 1, Z is wherein R^7 is hydrogen or (C_1-C_3)alkoxy; R^8 is hydrogen, hydroxy, or (C_1-C_3)alkoxy; and R^9 is (C_1-C_3)alkoxy; X is oxygen or NR, wherein R is hydrogen or (C_1-C_6)alkyl; Y is methylene, wherein n is 0, 1 or 2; or oxygen, nitrogen or sulfur, wherein n is 2, 3 or 4; R^1 and R^2 are each independently hydrogen, halogen, or a (C_1-C_6)alkyl, (C_1-C_6)alkoxy or a (C_1-C_6)alkoxy(C_1-C_6)alkyl group, any one of which groups may be unsbustituted or substituted with one or more halogens.

WO 2004/081007 A1

GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— *with international search report*